Patents by Inventor Kurt Naujoks

Kurt Naujoks has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of Administering Cationic Liposomes Comprising an Active Drug
    Publication number: 20080063699
    Abstract: The present invention relates to the use of pharmaceutical preparations comprising paclitaxel for administration to a human patient in need thereof.
    Type: Application
    Filed: October 15, 2004
    Publication date: March 13, 2008
    Inventors: Michael Teifel, Uwe Michaelis, Birgitta Sauer, Kerstin Bartelheim, Christoph Brunner, Kurt Naujoks
  • In vivo regeneration of oligodendrocytes by bolus injection of NGF&bgr;
    Patent number: 6268340
    Abstract: A method is presented for regenerating oligodendrocytes in diseases such as multiple sclerosis by administering human &bgr; nerve growth factor (NGF-&bgr;) by bolus injection. Treatment comprises 1-10 bolus injections in a dose of 0.05 to 5.0 &mgr;g/kg body at an interval of 1 to 21 days.
    Type: Grant
    Filed: September 8, 1997
    Date of Patent: July 31, 2001
    Assignee: Roche Diagnostics GmbH
    Inventors: Jürgen Unger, Ilse Bartke, Kurt Naujoks, Yorn Schmidt
  • Monoclonal antibodies against c-kit and method of detecting a malignancy using c-kit specific antibodies
    Patent number: 5545533
    Abstract: The invention concerns monoclonal antibodies against the human c-kit receptor which are obtainable from the cell lines DSM ACC 2007, DSM ACC 2008 and DSM ACC 2009 or are capable of binding to the c-kit receptor in an equivalent manner to the antibodies produced by the cell lines DSM ACC 2007, DSM ACC 2008 or DSM ACC 2009. The present invention also concerns a method for testing the malignancy of tumours of haematopoietic cells, of seminomas or small-celled lung carcinoma in which a tissue sample is incubated with at least one monoclonal antibody against the c-kit receptor according to the present invention and subsequently bound antibodies are detected by means of known methods.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: August 13, 1996
    Assignee: Boehringer Mannheim GmbH
    Inventors: Ilse Bartke, Gunter Kostka, Kurt Naujoks, Axel Ullrich
  • Process and monoclonal antibody for the specific determination of pancreatic .alpha.-amylase in the presence of salivary .alpha.-amylase
    Patent number: 5071744
    Abstract: Pancreatic .alpha.-amylase is determined in body fluid in the presence of salivary .alpha.-amylase by combining the body fluid with a monoclonal antibody that inhibits salivary .alpha.-amylase by 95% or more and inhibits pancreatic .alpha.-amylase by 50% or less, and then detecting pancreatic .alpha.-amylase with a system for the detection of .alpha.-amylase. The monoclonal antibody may be in immobilized form. The monoclonal antibody is preferably produced by immunizing a Balb/c mouse or an AJ mouse with a specific immunogen for a specific number of times, fusing .beta.-lymphocytes obtained from the mouse with a myeloma cell line to form an antibody producing hybridoma cell line, cloning and screening the hybridoma cell line for the desired monoclonal antibody, and isolating the monoclonal antibody. The immunogen contains modified or unmodified salivary .alpha.-amylase, aluminum hydroxide and Bortadella pertussis.
    Type: Grant
    Filed: October 9, 1990
    Date of Patent: December 10, 1991
    Assignee: Boehringer Mannheim GmbH
    Inventors: Kurt Naujoks, Karl Wulff, Martin Gerber